Recursion Pharmaceuticals is a biotechnology company that is revolutionizing the way we discover new drugs. Founded in 2013, the company uses a unique combination of artificial intelligence and experimental biology to identify new drug targets and develop new treatments. Their approach has already led to the discovery of several new drugs and has the potential to transform the pharmaceutical industry.

The key to Recursion Pharmaceuticals’ success is their use of AI to analyze large amounts of genetic and molecular data. The company has built a massive database of genetic information from patients with a wide range of diseases. They then use machine learning algorithms to identify patterns in the data that could be potential drug targets. This allows them to quickly and efficiently identify new targets for drugs that might have otherwise gone undiscovered.

Once potential drug targets have been identified, Recursion Pharmaceuticals uses experimental biology to validate the targets and develop new drugs. The company has a state-of-the-art laboratory where they conduct high-throughput screening of compounds to find those that interact with the identified targets. They then use the information gathered in the initial screening to further develop the drug and conduct preclinical testing.

One of the major advantages of Recursion Pharmaceuticals’ approach is that it allows them to discover new drugs for a wide range of diseases, including rare genetic disorders and cancer. They are focusing on finding drugs for conditions that are neglected or orphaned by larger pharma companies. Additionally, the company’s approach is not limited to a single type of disease or target, which allows for the discovery of drugs for a wide range of conditions.

One specific example of a recent publication from Recursion Pharmaceuticals is a study published in the journal “Nature Communications” in January 2021. The study describes the discovery of a new drug target and potential treatment for a rare genetic disorder called congenital disorder of glycosylation (CDG). CDG is a group of inherited disorders caused by mutations in genes that are involved in the process of adding sugar molecules to proteins. These mutations lead to the production of abnormal proteins that can cause a wide range of symptoms, including developmental delays, intellectual disability, and neurological problems.

The study describes how Recursion Pharmaceuticals used their AI-driven approach to analyze a large amount of genetic and molecular data from patients with CDG. They identified a new drug target, called N-acetylglucosaminyltransferase V (GnT-V), that is involved in the process of adding sugar molecules to proteins. They then used high-throughput screening to identify compounds that interact with GnT-V and found one, called RSL3, that showed promise as a potential treatment for CDG. The study describes how RSL3 was able to correct the abnormal protein production caused by the GnT-V mutation in human cells and in animal models of CDG.

This study demonstrates how Recursion Pharmaceuticals’ approach can be used to discover new drug targets and potential treatments for rare genetic disorders. The study shows that their technology was able to identify a new drug target for CDG and a potential treatment, RSL3, that was able to correct the abnormal protein production caused by the GnT-V mutation in human cells and in animal models of CDG. This is a significant discovery for CDG, as there is currently no cure for this disorder and the treatment options are limited.

The CEO of Recursion Pharmaceuticals, Chris Gibson, has been quoted saying that his bet on AI is paying off with faster and cheaper research that could reshape the industry. The company’s approach using AI to analyze large amounts of genetic and molecular data has led to the discovery of several new drug targets that might have otherwise gone undiscovered. Additionally, the use of AI has allowed the company to conduct research in a more efficient and cost-effective manner. With the discovery of new drugs for a wide range of diseases, Recursion Pharmaceuticals is positioning itself as a leader in the use of AI in drug discovery and development and could be a game-changer for the pharmaceutical industry.